Q4 EPS Estimate for ACADIA Pharmaceuticals Lifted by Analyst

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Stock analysts at Leerink Partnrs lifted their Q4 2024 earnings per share estimates for ACADIA Pharmaceuticals in a research report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will post earnings per share of $0.12 for the quarter, up from their previous estimate of $0.10. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals’ FY2025 earnings at $0.75 EPS, FY2027 earnings at $1.44 EPS and FY2028 earnings at $2.13 EPS.

ACAD has been the topic of several other reports. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. StockNews.com lowered shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Guggenheim downgraded ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $23.00 to $20.00 in a research report on Friday, January 3rd. Raymond James reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, October 10th. Finally, HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Seven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.25.

ACADIA Pharmaceuticals Stock Down 0.2 %

ACAD stock opened at $18.66 on Thursday. ACADIA Pharmaceuticals has a twelve month low of $14.15 and a twelve month high of $26.83. The stock has a market capitalization of $3.10 billion, a price-to-earnings ratio of 23.92 and a beta of 0.37. The firm’s fifty day simple moving average is $17.50 and its two-hundred day simple moving average is $16.64.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.06. The firm had revenue of $250.40 million for the quarter, compared to the consensus estimate of $248.83 million. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The company’s revenue for the quarter was up 18.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.40) EPS.

Insider Buying and Selling

In other news, CFO Mark C. Schneyer sold 10,259 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $172,453.79. Following the transaction, the chief financial officer now directly owns 53,302 shares of the company’s stock, valued at approximately $896,006.62. This represents a 16.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James Kihara sold 4,073 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $68,467.13. Following the transaction, the insider now directly owns 19,863 shares of the company’s stock, valued at $333,897.03. This represents a 17.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 24,661 shares of company stock worth $414,551 in the last ninety days. 28.30% of the stock is owned by insiders.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Park Place Capital Corp acquired a new position in shares of ACADIA Pharmaceuticals in the 3rd quarter valued at about $25,000. Values First Advisors Inc. purchased a new stake in ACADIA Pharmaceuticals in the 3rd quarter worth approximately $27,000. R Squared Ltd acquired a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $47,000. Quest Partners LLC increased its holdings in shares of ACADIA Pharmaceuticals by 42.3% during the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 1,047 shares in the last quarter. Finally, KBC Group NV increased its holdings in shares of ACADIA Pharmaceuticals by 67.0% during the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 2,044 shares in the last quarter. 96.71% of the stock is owned by hedge funds and other institutional investors.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.